Evidence map›Paper›PMID 26178154›Full record

ArticleHypertension research : official journal of the Japanese Society of Hypertension2015

Inhibitory effect of D1-like dopamine receptors on neuropeptide Y-induced proliferation in vascular smooth muscle cells.

Yongqiao Zhou, Weibin Shi, Hao Luo, Rongchuan Yue, Zhen Wang, Wei Wang, Li Liu, Wei Eric Wang, Hongyong Wang, Chunyu Zeng

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yongqiao ZhouDepartment of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, China.
Weibin ShiDepartment of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, China.
Hao LuoDepartment of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, China.
Rongchuan YueDepartment of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, China.
Zhen WangDepartment of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, China.
Wei WangDepartment of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, China.
Li LiuDepartment of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, China.
Wei Eric WangDepartment of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, China.
Hongyong WangDepartment of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, China.
Chunyu ZengDepartment of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, China.
Army Medical University · CNDaping Hospital · CNFirst Affiliated Hospital of Shantou University Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proliferation of vascular smooth muscle cells (VSMCs) is thought to have a key role in the development of atherosclerotic lesions. Neuropeptide Y (NPY), norepinephrine and dopamine are sympathetic neurotransmitters. NPY has been particularly shown to stimulate proliferation of VSMCs. NPY, norepinephrine and dopamine are all sympathetic transmitters. In our previous study, we found that in the presence of the dopamine receptor, the α1-adrenergic receptor-mediated VSMC proliferation is reduced. We hypothesize that the activation of the D1-like receptor might inhibit the NPY-mediated VSMC proliferation. In our present study, we found that NPY, mainly via the Y1 receptor, increased VSMC proliferation. This was determined by [(3)H]-thymidine incorporation, in a concentration (10(-11) to 10(-8)  M)-dependent manner. In the presence of the D1-like receptor agonist, fenoldopam (10(-12) to 10(-5) M), the stimulatory effect of NPY on VSMC proliferation was reduced. The involvement of the D1-like receptor was confirmed when the inhibitory effect of fenoldopam was reversed in the presence of the D1-like receptor antagonist SCH-23390 (10(-8) M). Moreover, the inhibitory effect of fenoldopam on NPY-mediated VSMC proliferation was also blocked in the presence of the PKA inhibitor 14-22 (10(-6)  M). Protein kinase A activator 8-(4-chlorophenylthio) adenosine-3,5-cyclic monophosphorothioate, Sp-isomer sodium salt (10(-6)  M) could simulate the stimulatory effect of fenoldopam. It indicated that the inhibitory effect of D1-like receptors on NPY-mediated VSMC proliferation may have an important role in the regulation of blood pressure or prevention of atherosclerosis.

Indexed as

AnimalsAtherosclerosisCell ProliferationCyclic AMP-Dependent Protein KinasesFenoldopamMaleMuscle, Smooth, VascularMyocytes, Smooth MuscleNeointimaNeuropeptide YRatsRats, Sprague-DawleyReceptors, Dopamine D1Cyclic AMP-Dependent Protein KinasesFenoldopamNeuropeptide YReceptors, Dopamine D1

Identifiers

PMID26178154
OpenAlexW1511252001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.